RLMDRELMADA THERAPEUTICS, INC.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$59M
- 30% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired2711× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$126M | −$161M | −$104M | −$84M | −$59M | 30% |
| Net income | −$126M | −$157M | $0 | $0 | $0 | |
| Operating cash flow | −$92M | −$104M | −$52M | −$52M | −$46M | 12% |
| Stock-based comp | $40M | $44M | $44M | $30M | $14M | 54% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $2M · 4
- Open-market sells, 12 mo
- $0 · 0
- Net
- $2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $9M | $19M | 15 | — |
| FY2024 | $2M | −$699K | 2 | — |
| FY2023 | $2M | $174K | 13 | — |